Revenue from the company's two drug products decreased 10% from the fourth quarter of 2018.
News & Analysis: Vanda Pharmaceuticals
VNDA earnings call for the period ending March 31, 2019.
The S&P 500 has rarely been more expensive than it is today. That doesn't mean bargain-hunting investors are out of luck.
This high-octane midstream stock, drug developer, and retail giant have the growth potential to send their shares skyward.
Two down-on-their-luck growth stocks are worth a closer look after a poor start to 2019.
Investors looking to inject growth into their portfolios should give these companies a closer look.
The pharma company reported fourth-quarter and full-year 2018 operating results.
VNDA earnings call for the period ending December 31, 2018.
The pharma company is taking the FDA to court over the regulator's insistence on animal testing.
Earnings per share will more than double for each of these specialty drugmakers.